Drugs / POSENACAFTOR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03251092 | Jul 2017 → Dec 2019 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03140527 Comparator | Apr 2017 → Feb 2020 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03500263 Comparator | Jan 2018 → Mar 2019 | cystic fibrosis | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POSENACAFTOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594274 ↗ |
| Known as | PTI-801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03140527 ↗ |
| Modality | Small molecule | — CHEMBL4594274 ↗ |